---
schema_version: "secwatch.filing_event.v1"
accession: "0001485003-23-000020"
form_type: "8-K"
ticker: "CARM"
cik: "0001485003"
company_name: "Carisma Therapeutics Inc."
filed_at: "2023-02-01T23:59:59+00:00"
generated_at: "2026-06-20T03:40:49.099688+00:00"
event_type: "litigation"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Class action securities litigation settlement receives final court approval

## Summary
- U.S. District Court for Southern District of New York granted final approval on January 31, 2023.
- Settlement resolves consolidated shareholder class action In re Sesen Bio, Inc. Securities Litigation.
- Derivative litigation previously received final approval by Massachusetts court on November 9, 2022.
- Settlement terms were previously disclosed in August 2022 Form 8-K.

## SEC filing metadata
- accession: 0001485003-23-000020
- form_type: 8-K
- ticker: CARM
- cik: 0001485003
- company_name: Carisma Therapeutics Inc.
- filed_at: 2023-02-01T23:59:59+00:00
- event_type: litigation
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1485003/000148500323000020/0001485003-23-000020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1485003/000148500323000020/sesn-20230131.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001485003-23-000020
- JSON: https://secwatch.observer/filing/0001485003-23-000020.json
- Plain text: https://secwatch.observer/filing/0001485003-23-000020.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.